MDNA News and Press, Medicenna Therapeutics Corp. From 04/18/23

TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participa...

-- IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues -- MDNA132 and MDNA213 are novel IL-13 Superkines that are highly specific and preferent...

- Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts - Continued tumor reduction and complete regression of one of three metastatic lesions in fourth-line pancreatic cancer patient wit...

TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted fo...

TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairma...

Summary Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 trial called ABILITY. A February 2023 update tells us MDNA stock has been able to increase the dose of MDNA11 without issues so far. The ABILITY trial is set to produce mor...

Medicenna Therapeutics Corp. (MDNA) Q3 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Dan Ferry - Investor Relations, LifeSci Advisors Fahar Merchant - President and Chief Executive Officer Liz Williams - Chief Financial Officer Co...

Medicenna Therapeutics press release ( NASDAQ: MDNA ): FQ3 GAAP EPS of -$0.02 beats by $0.05 . $36.2 million in cash and cash equivalents at December 31, 2022 For further details see: Medicenna Therapeutics GAAP EPS of -$0.02 beats by $0.05

Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY’s fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023 ...

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairm...